KNSA
NASDAQKiniksa Pharmaceuticals International plc
News · 26 weeks690%
2025-12-142026-06-07
Mix4790d
- Insider28(60%)
- SEC Filings12(26%)
- Other5(11%)
- Earnings2(4%)
Latest news
25 items- INSIDERDirector Quart Barry D converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Popovits Kimberly J converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHAIRMAN & CEO Patel Sanj K converted options into 900,000 units of Class A Ordinary Share (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Mccain Tracey L converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Malley Thomas converted options into 2,799 units of Class A Ordinary Shares, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Levy Richard S converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 15% to 21,956 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Cole G Bradley converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Baker Bros. Advisors Lp was granted 12,156 units of Class A Ordinary Shares (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SECKiniksa Pharmaceuticals International plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- PRKiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesLONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3 at 8:45 a.m. Eastern TimeGoldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9 at 11:20 a.m. Eastern Time A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharm
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kiniksa Pharmaceuticals International plcSCHEDULE 13D/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
- SECKiniksa Pharmaceuticals International plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plcSCHEDULE 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
- INSIDERCHIEF MEDICAL OFFICER Paolini John F. sold $3,137,823 worth of Class A Ordinary Share (58,424 units at $53.71) as part of a pre-agreed trading plan and exercised 58,424 units of Class A Ordinary Share at a strike of $10.36 (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SECSEC Form 144 filed by Kiniksa Pharmaceuticals International plc144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
- SECKiniksa Pharmaceuticals International plc filed SEC Form 8-K: Leadership Update8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- INSIDERCHAIRMAN & CEO Patel Sanj K exercised 48,565 units of Class A Ordinary Share at a strike of $30.93 and sold $2,623,481 worth of Class A Ordinary Share (48,565 units at $54.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERCHAIRMAN & CEO Patel Sanj K exercised 508,339 units of Class A Ordinary Share at a strike of $13.45 and sold $26,415,228 worth of Class A Ordinary Share (508,339 units at $51.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- INSIDERDirector Quart Barry D exercised 13,099 units of Class A Ordinary Share at a strike of $14.33 and sold $656,260 worth of Class A Ordinary Share (13,099 units at $50.10) as part of a pre-agreed trading plan (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SECSEC Form 144 filed by Kiniksa Pharmaceuticals International plc144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
- SECSEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc10-Q - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- SECKiniksa Pharmaceuticals International plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
- PRKiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –– Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today r
- PRKiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and reg
- SECSEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plcDEFA14A - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
KNSA FAQ
7 questionsWhat does Kiniksa Pharmaceuticals International plc do?
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase...Where does KNSA stock trade?
Kiniksa Pharmaceuticals International plc (KNSA) is listed on NASDAQ.What sector and industry is KNSA in?
Kiniksa Pharmaceuticals International plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kiniksa Pharmaceuticals International plc go public?
Kiniksa Pharmaceuticals International plc (KNSA) completed its IPO in 2018.What are analysts saying about KNSA?
Kiniksa Pharmaceuticals International plc has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-02-19. Recent price targets range from $3400.00 to $4000.00.What companies are similar to KNSA?
Notable peers in the same industry include MEIP (MEI Pharma Inc.), SYRS (Syros Pharmaceuticals Inc.), ALNA (Allena Pharmaceuticals Inc.), ARDS (Aridis Pharmaceuticals Inc.), RVPH (Reviva Pharmaceuticals Holdings Inc.). Compare KNSA side-by-side with any of them on Quantisnow.How can I track KNSA on Quantisnow?
Quantisnow aggregates Kiniksa Pharmaceuticals International plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KNSA to receive live email and push alerts on every new disclosure.